好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Associations Between MRI Changes and Cognitive Decline in Multiple Sclerosis: A Systematic Review and Meta-analysis
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
13-008

To systematically review longitudinal studies examining the relationship between MRI changes and cognitive changes in people with multiple sclerosis (MS) over ≥1 year follow-up.

While cross-sectional studies have examined neuroimaging correlates of cognition in MS, longitudinal data are limited. Understanding how cognitive decline relates to evolving neuroradiological changes remains a critical gap in MS research.

An extensive and methodical search of online databases was conducted to identify qualified studies until August 2023. Among various cognitive tests and magnetic resonance imaging (MRI) measures, Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), verbal fluency, T2 lesion volume (T2LV), white matter lesion volume (WML), and grey matter volume (GMV) qualified for inclusion in a meta-analysis investigating the association of cognitive changes to neuroradiological changes.

Thirty-five studies met inclusion criteria. Twenty studies (57%) examined SDMT/PASAT associations with MRI metrics, 11 (31%) focused on verbal learning/memory, 10 (29%) on visuospatial learning/memory, and 8 (23%) on verbal fluency. Five studies qualified for meta-analysis. Significant correlations were found between SDMT/PASAT and GMV (rs=0.67, 95% CI 0.44-0.91), and between verbal fluency and T2LV (rs=0.35, 95% CI 0.09-0.60).

Longitudinal cognitive decline in MS, particularly in SDMT/PASAT and verbal fluency, correlates significantly with grey matter atrophy and T2 lesion accumulation. However, findings are limited by heterogeneous methodologies, small sample sizes, and paucity of high-quality longitudinal studies. Future research should employ standardized cognitive batteries and advanced imaging techniques to better characterize brain-behavior relationships in MS progression.

Authors/Disclosures
Leila Simani, PhD
PRESENTER
Dr. Simani has nothing to disclose.
Victoria Leavitt, PhD, FAAN (Columbia University Irving Medical Center) Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Leavitt has received research support from National Institutes of Health. The institution of Dr. Leavitt has received research support from National Multiple Sclerosis Society. The institution of Dr. Leavitt has received research support from Department of Defense. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care.